|
4basebio PLC on Tuesday said it has promoted Chief Operating Officer Amy Walker to chief executive officer, succeeding founder Heikki Lanckriet. The Cambridge, England-based life sciences firm said after six years in the role, Lanckriet has stepped down to lead a nearly formed entity which will be focused on advancing the Hermes nanoparticle platform into the clinic. Lanckriet will remain on the board and will ‘continue to support the company’s scientific and technical leadership’. Chief Financial Officer David Roth will also join the newly formed entity and will step down from 4basebio after an ‘orderly handover period’. 4basebio said it has ‘top tier pharma clients in the clinic’ and a strong and growing pipeline. ‘With [good manufacturing practice] certification for its facility, the company is now accelerating its focus on commercial delivery. Amy has invaluable commercial, scientific and technical expertise and has spearheaded building out the GMP infrastructure to enable 4basebio to lead this dynamic market,’ said Executive Chair Manja Boerman. ‘I’m delighted that she will lead the company through this critical next phase of development and I look forward to leveraging my extensive [contract development and manufacturing organisation] experience in helping drive the business forward.’ Shares in 4basebio were up 13% at 630.00 pence on Tuesday afternoon in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
